DUBUQUE, Iowa — Nefense, a company specializing in clinical hygiene and airway health solutions, has officially launched its Hypochlorous Acid (HOCl) nasal spray line, designed to provide age-specific respiratory defense for adults, children, and infants. The announcement, made on June 4, 2026, introduces a product portfolio that aims to support airway health through a gentle, yet effective, antimicrobial and anti-inflammatory approach.
The flagship product, Hyponasal spray, offers a clinical-grade biocleanse that flushes irritants, provides soothing relief, and supports natural respiratory defenses without relying on harsh chemicals or steroids. According to Nefense, the formulation harnesses the power of hypochlorous acid, a substance naturally produced by the body's immune system, to deliver broad-spectrum antimicrobial action. This neutralizes bacteria and viruses, helps prevent upper respiratory infections, and combats seasonal allergies.
The launch comes as respiratory health gains increased attention, with consumers seeking alternatives to traditional medications. Hypochlorous acid has been recognized for its safety and efficacy in various hygiene applications, and its use in nasal care represents a novel approach to maintaining airway hygiene across different age groups. By offering formulations specifically designed for adults, children, and infants, Nefense addresses the varying needs and sensitivities of each demographic, potentially reducing the risk of misuse or overmedication.
Nefense developed the products in collaboration with doctors and ENT specialists, bridging the gap between daily hygiene and overall wellness. The company's existing portfolio includes XyloClean, a xylitol-based nasal spray that moisturizes and rebalances nasal passages. The new HOCl line is now available for in-store purchase at many clinics and practices nationwide, making it accessible to consumers seeking clinically inspired solutions for respiratory health.
The implications of this launch are significant for public health. By providing a non-pharmacological option for respiratory hygiene, Nefense's products could help reduce reliance on antibiotics and steroids, which often carry side effects and contribute to antimicrobial resistance. Additionally, the age-specific approach ensures that even the youngest patients can receive safe and effective care, potentially decreasing the incidence of upper respiratory infections and allergy symptoms without compromising safety.
As respiratory viruses and allergies continue to affect populations worldwide, innovations like Nefense's HOCl nasal spray offer a proactive tool for maintaining airway health. The company's commitment to science-driven hygiene solutions positions it at the forefront of a growing trend toward preventive care and natural defense mechanisms.
